妊娠期非青霉素非头孢菌素类抗菌药物的药代动力学与目标达成:系统综述第三部分
该系统综述检索PubMed并按PRISMA流程,纳入29项研究,覆盖18种非青霉素非头孢菌素类抗菌药物。妊娠期部分药物(利奈唑胺、庆大霉素、妥布霉素、莫西沙星)药代动力学改变,但未评估目标达成或开发循证剂量;万古霉素、克林霉素、利福平、利福喷丁、乙胺丁醇、吡嗪酰胺无需调整剂量,异烟肼结果矛盾。整体研究数量有限。
要点
- 妊娠期利奈唑胺、庆大霉素、妥布霉素、莫西沙星药代动力学改变,但缺乏目标达成数据和循证剂量。
- 万古霉素、克林霉素、利福平、利福喷丁、乙胺丁醇、吡嗪酰胺在妊娠期可能无需调整剂量。
- 异烟肼妊娠期目标达成研究结果矛盾,需个体化评估。
核心结论
- 针对非青霉素非头孢菌素类抗菌药物在妊娠期药代动力学的研究非常有限,多数药物缺乏目标达成评估和循证剂量推荐。
研究设计与样本
- 系统综述,按PRISMA指南在PubMed检索,两名研究者独立完成筛选与数据提取,最终纳入29项研究,覆盖18种药物。
主要发现
- 29项研究中,3项涉及氨基糖苷类,1项碳青霉烯类,6项喹诺酮类,4项糖肽类,2项利福霉素类,1项磺胺类,5项抗结核药,6项其他。
- 利奈唑胺、庆大霉素、妥布霉素和莫西沙星在妊娠期(尤其第二、三孕期)药代动力学改变,但未研究目标达成,未开发循证剂量。
- 万古霉素、克林霉素、利福平、利福喷丁、乙胺丁醇和吡嗪酰胺的目标达成能力已评估,前六种药物似无需妊娠期剂量调整。
- 异烟肼的研究结果相互矛盾。
临床怎么用
- 临床使用利奈唑胺、庆大霉素、妥布霉素或莫西沙星时,应意识到妊娠期药代动力学可能改变,但现有证据不足以支持常规剂量调整,需密切监测。
- 万古霉素、克林霉素、利福平、利福喷丁、乙胺丁醇和吡嗪酰胺在妊娠期可能无需调整剂量,但仍需结合患者具体情况。
- 异烟肼在妊娠期的目标达成存在争议,建议个体化评估和监测。
局限性
- 仅29项研究纳入,覆盖18种药物,多数药物证据缺乏。
- 部分药物仅报告浓度或药代动力学数据,未评估目标达成或开发循证剂量。
- 异烟肼研究结果矛盾,可能受研究异质性影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Understanding the pharmacokinetics (PK) of antimicrobial drugs in pregnant women is crucial to provide effective and safe treatment. This study is part of a series that systematically reviews literature on the PK and analyzes if, based on the changed PK, evidence-based dosing regimens have been developed for adequate target attainment in pregnant women. This part focusses on antimicrobials other than penicillins and cephalosporins. METHODS: A literature search was conducted in PubMed according to the PRISMA guidelines. Search strategy, study selection, and data extraction were independently performed by two investigators. Studies were labeled as relevant when information on the PK of antimicrobial drugs in pregnant women was available. Extracted parameters included bioavailability for oral drugs, volume of distribution (Vd) and clearance (CL), trough and peak drug concentrations, time of maximum concentration, area under the curve and half-life, probability of target attainment, and minimal inhibitory concentration (MIC). In addition, if developed, evidence-based dosing regimens were also extracted. RESULTS: Of the 62 antimicrobials included in the search strategy, concentrations or PK data during pregnancy of 18 drugs were reported. Twenty-nine studies were included, of which three discussed aminoglycosides, one carbapenem, six quinolones, four glycopeptides, two rifamycines, one sulfonamide, five tuberculostatic drugs, and six others. Eleven out of 29 studies included information on both Vd and CL. For linezolid, gentamicin, tobramycin, and moxifloxacin, altered PK throughout pregnancy, especially in second and third trimester, has been reported. However, no target attainment was studied and no evidence-based dosing developed. On the other hand, the ability to reach adequate targets was assessed for vancomycin, clindamycin, rifampicin, rifapentine, ethambutol, pyrazinamide, and isoniazid. For the first six mentioned drugs, no dosage adaptations during pregnancy seem to be needed. Studies on isoniazid provide contradictory results. CONCLUSION: This systematic literature review shows that a very limited number of studies have been performed on the PK of antimicrobials drugs-other than cephalosporins and penicillins-in pregnant women.
引用
- Groen F, Prins JR, Hooge MNL, et al. The Pharmacokinetics and Target Attainment of Antimicrobial Drugs Throughout Pregnancy: Part III Non-penicillin and Non-cephalosporin Drugs. Clin Pharmacokinet. 2023. PMID: 36940039. doi:10.1007/s40262-023-01226-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。